? 關(guān)鍵詞 奧希替尼 納武利尤單抗 肉毒毒素 循環(huán)腫瘤 DNA測(cè)序 維布妥昔單抗 依庫(kù)珠單抗 呋喹替尼 非酒精性脂肪性肝炎 ?

#今日行業(yè)熱點(diǎn)#

①The New England Journal of Medicine：Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC 臨床試驗(yàn)：第三代表皮生長(zhǎng)因子受體酪氨酸激酶抑制劑奧希替尼單藥或聯(lián)合化療用于EGFR突變晚期非小細(xì)胞肺癌（NSCLC） DOI: 10.1056/NEJMoa2306434

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC | NEJM

②The New England Journal of Medicine：Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma 臨床試驗(yàn)：納武利尤單抗（Nivolumab）聯(lián)合鉑類(lèi)藥物用于晚期尿路上皮癌的Ⅲ期、多國(guó)、開(kāi)放標(biāo)簽試驗(yàn) DOI: 10.1056/NEJMoa2309863

Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma | NEJM

③The New England Journal of Medicine：Trial of Botulinum Toxin for Isolated or Essential Head Tremor 臨床試驗(yàn)：肉毒毒素用于孤立性或原發(fā)性頭部震顫的試驗(yàn)：一項(xiàng)多中心、雙盲、隨機(jī)試驗(yàn) DOI: 10.1056/NEJMoa2304192

Trial of Botulinum Toxin for Isolated or Essential Head Tremor | NEJM

④Blood：Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA 研究：超敏感的循環(huán)腫瘤(CT)DNA測(cè)序在中樞神經(jīng)系統(tǒng)淋巴瘤(CNSL)的作用 DOI: 10.1182/blood.2023022020

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA | Blood | American Society of Hematology (ashpublications.org)

⑤Blood：Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy in older patients ineligible for chemotherapy 臨床數(shù)據(jù)：抗體偶聯(lián)藥物（ADC）維布妥昔單抗(Brentuximab vedotin)聯(lián)合達(dá)卡巴嗪或納武利尤單抗用于老年經(jīng)典型霍奇金淋巴瘤（cHL） DOI: 10.1182/blood.2022019536

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy in older patients ineligible for chemotherapy | Blood | American Society of Hematology (ashpublications.org)

⑥Blood：Prospective Multi-Institutional Study of Eculizumab?to Treat High-Risk Stem Cell Transplant Associated TMA 依庫(kù)珠單抗（Eculizumab）用于高危干細(xì)胞移植相關(guān)血栓性微血管?。═MA）的前瞻性多機(jī)構(gòu)研究 DOI: 10.1182/blood.2023022526

Prospective Multi-Institutional Study of Eculizumab to Treat High-Risk Stem Cell Transplant Associated TMA | Blood | American Society of Hematology (ashpublications.org)

⑦VEGFR抑制劑呋喹替尼獲FDA批準(zhǔn)上市，用于既往使用過(guò)氟嘧啶、奧沙利鉑和伊立替康的轉(zhuǎn)移性結(jié)直腸癌 ⑧靶向CD47的SIRPαFc融合蛋白IMM01獲FDA授予孤兒藥資格，聯(lián)合阿扎胞甘用于慢性粒單核細(xì)胞白血?。–MML） ⑨CDK4選擇性抑制劑BGB-43395注冊(cè)一項(xiàng)Ⅰ期臨床試驗(yàn)，擬評(píng)估單藥或聯(lián)合氟維司群或來(lái)曲唑用于HR+/HER 2-乳腺癌（BC）和其他晚期實(shí)體瘤 ⑩甲狀腺激素β受體（THR-β）選擇性激動(dòng)劑KH629獲FDA批準(zhǔn)開(kāi)展新藥研究，擬開(kāi)發(fā)用于非酒精性脂肪性肝炎（NASH） 科學(xué)探索的世界充滿(mǎn)挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴(lài)的合作伙伴！